P736 Utility of infliximab serum concentration in inflammatory bowel disease treatment in real world practice at Hospital Universitario de Canarias
ECCO'20 Vienna
2020
P737 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
ECCO'20 Vienna
2020
P738 Real world outcomes on the efficacy and safety of combination of biologic and immunosuppressive therapy in liver transplant recipients with inflammatory bowel disease
ECCO'20 Vienna
2020
P739 Patients with Crohn’s disease with intestinal failure have less active disease than patients with Crohn’s disease without intestinal failure
ECCO'20 Vienna
2020
P741 Incidence and clinical phenotype of inflammatory bowel disease in the north–west of Spain (Vigo) between 1991 and 2011
ECCO'20 Vienna
2020
P742 Morbidity and mortality outcomes of paediatric-onset inflammatory bowel disease in early adult life: A Scottish population-based, nested case–control study
ECCO'20 Vienna
2020
P746 Prevalence, features and outcomes of splachnic vein thrombosis in inflammatory bowel disease. A nationwide, retrospective study from the ENEIDA registry
ECCO'20 Vienna
2020
P747 Adherence to ECCO guidelines for cancer surveillance is associated to the detection of early cancer: A retrospective, single-centre, cohort study
ECCO'20 Vienna
2020
P748 Characteristics of inflammatory bowel diseases in different stage of adolescence
ECCO'20 Vienna
2020
P750 Prevalence and characteristics of incidentally diagnosed inflammatory bowel disease during screening colonoscopy
ECCO'20 Vienna
2020
P751 Prevalence and risk factors of non-alcoholic fatty liver disease in inflammatory bowel diseases
ECCO'20 Vienna
2020
P752 A nationwide survey of chronic enteropathy associated with SLCO2A1 gene in Japan
ECCO'20 Vienna
2020
P753 Elevation of liver enzymes in a large cohort of patients with inflammatory bowel disease
ECCO'20 Vienna
2020